Chugai Pharmaceutical Announcement Anti-Cancer Agent Tarceva Tablet Approved in Japan (Japan)
This article was originally published in PharmAsia News
Executive Summary
Chugai Pharmaceutical Co. announced Oct. 22 that the Japanese Ministry of Health Labour and Welfare has granted approval to Tarceva. The drug has been approved for use in patients with certain types of lung-cancer that can be aggravated by chemotherapy. The Ministry of Health's decision comes on the heels of several successful clinical trials which revealed Tarceva was safe and effective and had a low incidence of side effects. The drug has been approved for marketing in doses of 25 mg, 100 mg, and 150 mg. (Click here for more